TENORMIN (atenolol) by Lavipharm is adrenergic beta-antagonists [moa]. First approved in 1981.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
TENORMIN (atenolol) is a selective beta-1 adrenergic blocker approved in 1981 for cardiovascular indications including hypertension and angina. It reduces heart rate and blood pressure by blocking beta-adrenergic receptors, decreasing cardiac workload. The drug is administered orally as a tablet and remains a foundational agent in cardiovascular therapy.
Mature product with minimal spending and declining claims indicates small commercial team focused on market maintenance rather than expansion.
Adrenergic beta-Antagonists
beta-Adrenergic Blocker
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension
Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure
Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects
Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
Worked on TENORMIN at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on TENORMIN offers limited growth opportunity but stable, defensive experience in mature brand management, generic strategy, and cost-based competition. Roles focus on operational efficiency, market access, and compliance rather than innovation or commercial expansion.